# Pizarra — PT-pseudo_4e545d350c5b (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4e545d350c5b
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 22.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.696 ng/mL²
  - PSA velocity: 2.9 ng/mL/yr
  - Prior PSA: 19.9 ng/mL
  - Prostate volume: 31.63 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8591883 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Penicillin (rash)
  - Additional notes: PSA 22 ng/mL. PI-RADS 5. PSAD 0.70. Prostate volume 32 mL. csPCa 0.86.

Vitals: weight 85 kg, height 181 cm, BMI 25.9, BP 120/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (20 pack-yr, quit 2013).

Chief complaint: Persistent prostate-specific antigen elevation alongside recent imaging findings prompted this consultation.

History: Serial prostate-specific antigen measurements demonstrating a steady climb initiated a prolonged urological evaluation for this 68-year-old man. He works as a retired firefighter and resides with his partner, maintaining a brisk pace through weekend hikes. Lower urinary tract complaints surface moderately, yielding an IPSS of 10 driven mainly by occasional hesitancy and mild nocturia. He firmly denies unexplained weight loss, pelvic discomfort, or blood in the urine. Medical background remains clear apart from a distant appendectomy during his twenties and a recent dermatology appointment for actinic keratosis treatment. Former smoking habits total 20 pack-years, though he ceased tobacco use in 2013. Alcohol intake averages nine units each week. Mild visual impairment dictates large-print correspondence, and his adult daughter acts as his main liaison. An autumn 2024 cardiology assessment confirmed steady cardiovascular health without any current prescriptions. Comorbid conditions are absent. Marital status is divorced.

Physical examination: DRE: texture smooth and uniform; mobility intact; no focal nodules or dimensional irregularities detected. The gland measures within normal parameters and presents bilaterally symmetric. General assessment shows stable vital markers and absence of lymphadenopathy or systemic disease indicators. Nutritional status appears robust, and functional mobility remains excellent.

Patient info: retired firefighter; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 9 units / week; exercise Hiking on weekends; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Dermatology — actinic keratosis check.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.89 +/- 0.10   (95% CI 0.62-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.03  (few labelled cases resemble this one)
  - 8.1 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=22.0, age=68.0, psad=0.696, dre_ord=0.0, vol=31.63, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=22.0, age=68, PSA density=0.696, DRE=Normal, Volume=31.63 mL, Prior biopsy=None) and failed to incorporate the PSA velocity (2.9 ng/mL/yr) or the csPCa predicted probability (0.8591883).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.89), but the guideline criterion is based only on PI-RADS $\ge 3$, which is met, but the prior ignores the context of the rising PSA and the high csPCa probability. The prior's high confidence interval suggests the decision is robust, but this ignores the possibility that the rising PSA might be an outlier or that the high probability is driven by factors not fully captured by the limited feature set.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology notes
family-history of prostate cancer (anamnesis)
GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and this decision is constrained by the context of PSA density and family history.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4e545d350c5b", "radiology_report": "PI-RADS 5 lesion in the right posterior peripheral zone. Lesion dimensions: 18 x 14 x 12 mm. No extracapsular extension or seminal vesicle invasion noted."}
get_psa_trend
{"case_id": "PT-pseudo_4e545d350c5b", "psa_trend": [{"date": "Feb 2023", "val": 11.9}, {"date": "Oct 2023", "val": 15.7}, {"date": "Jun 2024", "val": 11.7}, {"date": "Feb 2025", "val": 22.0}]}
get_previous_notes
{"case_id": "PT-pseudo_4e545d350c5b", "previous_notes": [{"date": "14 Jun 2024", "author": "Dr. N. Kuiper (GP)", "text": "A PSA reading of 19.9 ng/mL prompted a routine clinical review. We examined the consistent upward trend observed since the first elevation in February 2023 and emphasized the necessity for specialist urological evaluation. Arrangements for a multiparametric MRI and dedicated assessment are now in place."}, {"date": "15 Feb 2024", "author": "Dr. N. Kuiper (GP)", "text": "Clinical follow-up centered on a PSA measurement of 17.8 ng/mL. Physicians reviewed the progressive climb documented since early 2023, and the patient received counseling on potential clinical implications. Voiding function remains entirely symptom-free."}]}
get_lab_results
{"case_id": "PT-pseudo_4e545d350c5b", "laboratory_results": [{"name": "PSA", "val": "22.0 ng/mL", "date": "07 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "4.73 ng/mL", "date": "07 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "07 Jan 2025", "flag": ""}]}
NOT RETRIEVED
The ISUP grade group or Gleason score of any prior biopsy was not documented, which is needed to assess if the prior cancer is a treatment problem.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the right posterior peripheral zone.
- PSA trend: Rising from 11.9 ng/mL (Feb 2023) to 22.0 ng/mL (Feb 2025), with a velocity of 2.9 ng/mL/yr.
- Guideline criterion: PI-RADS 5 meets the criterion for biopsy ($\ge 3$).
AGAINST sampling this patient now:
- mpMRI report: No extracapsular extension or seminal vesicle invasion noted.
- DRE findings: Normal.
- Previous notes: No mention of an active surveillance protocol or planned treatment.
WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the high-risk MRI finding (PI-RADS 5) and the significant, sustained rise in PSA. This confirms the statistical prior but emphasizes the need for tissue characterization.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI revealed a PI-RADS 5 lesion, which meets the guideline criterion for biopsy. This finding was supported by the rising PSA trend, which increased from 11.9 ng/mL in Feb 2023 to 22.0 ng/mL in Feb 2025. The statistical prior and the guideline criterion converged on this decision, and no retrieved evidence contradicted the need for tissue characterization.

Variables that carried weight: age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
